Press Release
Hybrigenics : green light for two European patents protecting new oral formulations of inecalcitol Hybrigenics obtains patent protection until 2031 for innovative oral formulations optimized for the delivery of high doses of inecalcitol
Paris, October 9th, 2012 - Hybrigenics
(ALHYG), a bio-pharmaceutical company
listed on Alternext (NYSE-Euronext) in Paris,
with a focus on research and development of new treatments
against proliferative diseases, today announces it has
received from the European Patent Office the official
notification of its intent to grant, after an accelerated
examination procedure, two patents on new pharmaceutical
formulations allowing a better absorption of inecalcitol.
One patent covers innovative tablets, an unusual formulation
for a vitamin D receptor agonist like inecalcitol. The other
patent protects a second generation of soft gelatin capsules
with a higher concentration of inecalcitol. The chronic
lymphocytic leukemia patients treated in the ongoing Phase II
clinical study of inecalcitol receive one 2-milligram tablet
every day.
Filed in 2010 (cf Hybrigenics' press release of November
2nd, 2010), this patent application has been
reviewed and approved in just 2 years by the European Patent
Office, like two other patent applications on the therapeutic
use of high doses of inecalcitol (cf Hybrigenics' press
release of January 24th, 2011) and on a key step
in the chemical synthesis of inecalcitol (cf Hybrigenics'
press release of February 27th, 2012). All other
examinations are progressing smoothly for the rest of the
world under the normal PCT or American procedures.
"Our patenting strategy has proved to be relevant and its
execution extremely efficient, given the approval rate and
speed of examinations," explained Rémi Delansorne,
Hybrigenics' CEO. "Hybrigenics now definitively owns four
patent families ensuring exclusive commercialization of oral
inecalcitol up to 2031."
About Hybrigenics : Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold- standard chemotherapeutic treatment for this indication. Oral inecalcitol has recently been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is currently being tested in chronic lymphocytic leukemia patients. Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two- Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.
*** HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris ISIN: FR0004153930 - Ticker: ALHYG Hybrigenics Rémi Delansorne CEOTel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com
NewCap.Financial communication
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.fr
distributed by |